ClinicaliQ Trial Snapshot
- Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) — Active Not Recruiting • Phase III • NCT05653349.
- Ianalumab added to steroids didn't improve platelet counts better than steroids alone in newly diagnosed ITP patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ≥30 G/L in adult participants with primary ITP. Conditions: Primary Immune Thrombocytopenia (ITP) Interventions: Ianalumab, Placebo, Corticosteroids Lead Sponsor: Novartis Pharmaceuticals Planned Enrollment: 226 participants